AG Combined With Immunotherapy and SBRT in Patients With Potentially Resectable Pancreatic Cancer
Status:
Not yet recruiting
Trial end date:
2026-06-06
Target enrollment:
Participant gender:
Summary
The objective of this study is to evaluate the efficacy and safety of concurrent
chemoradiotherapy combined with immunotherapy in patients with potentially resectable
pancreatic cancer.
Phase:
Phase 2
Details
Lead Sponsor:
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Collaborators:
Fudan University Shanghai Changzheng Hospital The First Affiliated Hospital of Soochow University The First Affiliated Hospital with Nanjing Medical University Xuzhou Central Hospital